Noel Alan R, Attwood Marie, Bowker Karen E, MacGowan Alasdair P, Albur Maha
Bristol Centre for Antimicrobial Research & Evaluation (BCARE), Severn Infection Sciences, Pathology Quarter, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
J Antimicrob Chemother. 2022 Apr 27;77(5):1306-1312. doi: 10.1093/jac/dkac026.
There is surprisingly little comparative published data on the bactericidal action of different sub-classes of β-lactams against aerobic Gram-negative rods, and the assumption is that all behave in the same way.
To describe a systematic investigation of a representative penicillin, cephalosporin, monobactam and carbapenem against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa.
Concentration-time-kill curves (TKC) were determined for three strains each of E. coli, K. pneumoniae, A. baumannii and P. aeruginosa. All strains were susceptible to the agents used. The antibiotics were piperacillin/tazobactam, ceftazidime, aztreonam and meropenem. The initial inoculum was 106 cfu/mL and TKC were determined over 48 h. The area-under-the-bacterial-kill curve to 24 h (AUBKC 24 log cfu·h/mL) and 48 h (AUBKC 48) were used to measure antibacterial effect (ABE). Population profiles before and after antibiotic exposure were recorded.
Against E. coli and K. pneumoniae meropenem had a maximal ABE at ≥MIC × 1 concentrations while piperacillin/tazobactam and ceftazidime had maximal effect at ≥MIC × 4 and aztreonam at ≥MIC × 8 concentrations. Ceftazidime, aztreonam and meropenem had less ABE against K. pneumoniae than E. coli. Against P. aeruginosa, meropenem was most bactericidal, with a maximum ABE at 8×/16 × MIC. Other β-lactams had notably less ABE. In contrast, against A. baumannii, ceftazidime and meropenem had the greatest ABE, with a maximal effect at ≥MIC × 4, concentration changes in population profiles were least apparent with E. coli.
β-Lactam sub-classes (penicillins, cephalosporins, monobactams and carbapenems) have different antibacterial effects against E. coli, K. pneumoniae, A. baumannii and P. aeruginosa. Extrapolation of in vitro pharmacodynamic findings from one species to another or one sub-class of β-lactam to another is not justified.
令人惊讶的是,关于不同亚类β-内酰胺类药物对需氧革兰氏阴性杆菌的杀菌作用,公开的比较数据很少,人们认为它们的作用方式相同。
描述对一种代表性青霉素、头孢菌素、单环β-内酰胺类和碳青霉烯类药物针对大肠埃希菌、肺炎克雷伯菌、鲍曼不动杆菌和铜绿假单胞菌的系统研究。
测定了大肠埃希菌、肺炎克雷伯菌、鲍曼不动杆菌和铜绿假单胞菌各三株菌株的浓度-时间杀菌曲线(TKC)。所有菌株对所用药物均敏感。抗生素为哌拉西林/他唑巴坦、头孢他啶、氨曲南和美罗培南。初始接种量为106 cfu/mL,在48小时内测定TKC。使用24小时(AUBKC 24 log cfu·h/mL)和48小时(AUBKC 48)的细菌杀灭曲线下面积来衡量抗菌效果(ABE)。记录抗生素暴露前后的群体分布情况。
对于大肠埃希菌和肺炎克雷伯菌,美罗培南在≥MIC×1浓度时具有最大的ABE,而哌拉西林/他唑巴坦和头孢他啶在≥MIC×4浓度时具有最大效果,氨曲南在≥MIC×8浓度时具有最大效果。头孢他啶、氨曲南和美罗培南对肺炎克雷伯菌的ABE低于对大肠埃希菌的ABE。对于铜绿假单胞菌,美罗培南的杀菌作用最强,在8×/16×MIC时具有最大的ABE。其他β-内酰胺类药物的ABE明显较低。相比之下,对于鲍曼不动杆菌,头孢他啶和美罗培南的ABE最大,在≥MIC×4浓度时具有最大效果,大肠埃希菌群体分布的浓度变化最不明显。
β-内酰胺类亚类(青霉素类、头孢菌素类、单环β-内酰胺类和碳青霉烯类)对大肠埃希菌、肺炎克雷伯菌、鲍曼不动杆菌和铜绿假单胞菌具有不同的抗菌效果。将一种细菌的体外药效学研究结果外推至另一种细菌,或从一种β-内酰胺类亚类外推至另一种β-内酰胺类亚类是不合理的。